BMY
Bristol Myers SquibbNYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-05-08
As of May 8, 2026, BMY has a composite score of 7.7, with a signal label of "mixed" and a medium confidence level of 71.4. The score is influenced by various factors, including a macro score of 31.5 and a sector score of 7.6. Key drivers include macroeconomic conditions related to labor, rates, growth, and inflation. This analysis is provisional.
Price
Daily closes from AlphaVantage. Earnings/event dots are placed inline.
Factor signals
Read top-to-bottom: thesis (is this a strong company over a 1–3 year hold), watch flags (has something changed worth re-reading), and position context (how violent might the path be). Each pill is a parallel diagnostic — never aggregated into a single score.
Thesis
— is this a strong company over a 1–3 year hold?Why this rank
- Direction share-0.46
- Slope (norm)0.68
- Bonus0.24
Why this rank
Trailing four: 2024-Q3, 2025-Q1, 2025-Q2, 2025-Q3
Why this rank
Watch
— has something changed worth re-reading?Why this setup
EPS estimate $1.66 → $1.62 (-2.7% / 30d). 5 raised, 9 cut, 21 covering analysts.
0 upgrades, 0 downgrades / 30d, 1 maintained. 34% of analysts rate Buy.
0 positive, 0 negative / 30d.
F4 · Management deep-dive — recent events, stated priorities, guidance track record
Recent 8-K events
1 material event in the last 24 months — top 1 listed below.
Stated priorities
2 priorityies extracted from earnings transcripts (as of 2026-05-08).
- 1.Reaffirm 2026 financial guidancegrowthbehind19% progress
4/30: “Bristol Myers Squibb is reaffirming its 2026 financial guidance with total revenues and diluted EPS trending toward the upper end of the ranges.”
Why this status
Stated in 2 of last 2 quarters. Revenue guidance range is $46.0 billion to $47.5 billion, and EPS guidance range is $6.05 to $6.35. Despite reaffirmation, financial results showed a net income loss of $548 million in 2025-Q4, indicating limited progress toward achieving the upper end of guidance.
- 2.Maintain gross margin guidancecostbehind0% progressprovisional
2/5: “Gross Margin % ~69% - 70%”
Why this status
Newly stated in 2025-Q4. The company has set a gross margin guidance of 69% to 70% for 2026. However, the financials for 2025-Q4 show an operating income loss of $1.75 billion, suggesting challenges in maintaining the desired margin.
Guidance track record
Insufficient guidance history for this ticker.
Position context
— how violent might the path be while I hold it?Why this risk level
Recent vol — 30d annualized 29%; 252d 28%.
Drawdown — Max 1y −14%. Bad day move −2%.
Beta to sector ETF (XLV) — 1.18 over 1y.
Liquidity — score 100/100.
Sub-scores — vol 54/100, drawdown 73/100, beta 82/100, earnings vol —.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive — historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only — describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-05-08.
What changed
The most important moves since the prior daily snapshot.
- No material changes since the prior snapshot.
No material changes since the prior snapshot.
as of 2026-05-08
Management scorecard
How management runs the business — capital, margins, balance sheet, and how reliably they guide and deliver.
What management is focused on
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
- #1
Reaffirm 2026 financial guidance
GrowthNew since 2026-05-04Bristol Myers Squibb is reaffirming its 2026 financial guidance with revenues and EPS trending toward the upper end of the provided ranges.
BehindStated in 2 of last 2 quarters. Revenue guidance range is $46.0 billion to $47.5 billion, and EPS guidance range is $6.05 to $6.35. Despite reaffirmation, financial results showed a net income loss of $548 million in 2025-Q4, indicating limited progress toward achieving the upper end of guidance.
19%CEO/CFO:“Bristol Myers Squibb is reaffirming its 2026 financial guidance with total revenues and diluted EPS trending toward the upper end of the ranges.”Multiple sourcesSource dated 2026-04-30Stated 2 of last 8 quartersFirst seen 2026-05-04Show history (2)
- 2026-Q1Multiple sources
“Reaffirming its 2026 financial guidance with total revenues and diluted EPS trending toward the upper end.”
- 2025-Q4Multiple sources
“Reaffirming its 2026 financial guidance with total revenues and diluted EPS trending toward the upper end.”
- #2
Maintain gross margin guidance
CostNew since 2026-05-04Bristol Myers Squibb aims to maintain its gross margin guidance of 69% to 70% for 2026.
BehindNewly stated in 2025-Q4. The company has set a gross margin guidance of 69% to 70% for 2026. However, the financials for 2025-Q4 show an operating income loss of $1.75 billion, suggesting challenges in maintaining the desired margin.
0%CEO/CFO:“Gross Margin % ~69% - 70%”Multiple sourcesSource dated 2026-02-05Stated 1 of last 8 quartersFirst seen 2026-05-04provisionalShow history (1)
- 2025-Q4Multiple sources
“Gross Margin % ~69% - 70%”
How this stock is priced
Two ways to read price: against peers in the same business, and against the company's own history.
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
P/E over the last 5 years
2 monthly pointsHow this compares
A side-by-side read on composite, valuation, and risk versus peers.
| Stock | Composite | Valuation | Risk |
|---|---|---|---|
BMY Bristol Myers Squibb | +7.7 | inexpensive | moderate |
LLY Lilly (Eli) | +21 | full | moderate |
JNJ Johnson & Johnson | +18 | full | low |
ABBV AbbVie | +12 | fair | low |
UNH UnitedHealth Group | +24 | fair | elevated |
Risk — how this stock moves
What a normal day looks like, what a bad day looks like, and the worst the last year has thrown at it.
What could change this view
Conditional scenarios — if X happens, the score would shift by about Y points. These are not predictions.
- If health_care sector trend rises from +0.06 into 'improving' (>= +0.20)+5.0 pts
- If next-quarter guidance is raised (currently NEW as of 2026-04-30)+4.0 pts
- If next-quarter guidance is cut (currently NEW as of 2026-04-30)-8.0 pts
- If labor state reverses from -0.31 (negative) to +0.31 (positive)-6.8 pts
- If health_care sector trend falls from +0.06 into 'weakening' (<= -0.20)-5.0 pts
Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-04-308d agoItem 2.02
Results of Operations and Financial Condition. On April 30, 2026, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) on its website at www.bms.com announcing its financial results for the first quarter of 2026. A copy of the Earnings Press Release is furnished pursuant to this
earnings preannouncementneutralscore 54 - 2026-02-053mo agoItem 2.02
Results of Operations and Financial Condition. On February 5, 2026, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) on its website at www.bms.com announcing its financial results for the fourth quarter of 2025 and full year of 2025. A copy of the Earnings Press Release is furnished pursuant to this
earnings preannouncementnegativescore 9
Score history
The composite score, snapshot by snapshot. The dotted line at zero separates leaning-positive from leaning-negative.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.